Sanara MedTech(US:SMTI)2026-01-23 12:45Revenue Projections - Net revenue for Q4 2025 is expected to be between $27.2 million and $27.7 million, representing a year-over-year increase of approximately 3% to 5% compared to $26.3 million in Q4 2024[4]. - Full year 2025 net revenue is projected to be in the range of $102.7 million to $103.2 million, reflecting a growth of approximately 19% compared to $86.7 million in 2024[4]. - Excluding BIASURGE sales from Q4 2024, net revenue for Q4 2025 is expected to increase approximately 11% to 13% year-over-year[4]. - Full year 2026 net revenue is expected to range from $116 million to $121 million, indicating growth of approximately 13% to 17% compared to the midpoint of the expected net revenue for 2025[5]. - The expected net revenue growth for 2026 is primarily driven by sales of soft tissue products[5]. Financial Position - The company had cash of approximately $16.6 million and long-term debt of $46.0 million as of December 31, 2025, compared to cash of $15.9 million and long-term debt of $30.7 million as of December 31, 2024[4]. Product Development and Market Strategy - The company plans to introduce the OsStic Synthetic Injectable Structural Bio-Adhesive to the U.S. market in Q1 2027, pending FDA clearance[4]. - BIASURGE received an Innovative Technology contract from Vizient, expanding access to the product at contracted pricing effective January 1, 2026[4]. - The company aims to enhance its sales and distribution network while expanding its product portfolio through initiatives with Biomimetic Innovations Ltd[5]. - The company is positioned as a pure play surgical business, targeting sustainable long-term growth in the multi-billion-dollar surgical solutions market[5].